All In Biotech

Free tool

FAERS Monitor: Auvelity

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215430 or its brand name (Auvelity, Bupropion Hydrochloride, Dextromethorphan Hydrobromide). Reports on generic versions are filed under their own applications.

Reports

3,564

Serious

841

24% of reports

Hospitalization

199

Death reported

36

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness328
  • feeling abnormal286
  • drug ineffective230
  • anxiety228
  • inappropriate schedule of product administration185
  • nausea179
  • fatigue177
  • depression175
  • off label use175
  • headache155
  • therapy interrupted154
  • tremor130
  • suicidal ideation128
  • somnolence116
  • insomnia113

Reports by year received

View as table
YearReports
20203
20212
202217
2023687
2024944
20251,091
2026820

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,595 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
therapy interruptedSignal15412.710.91,657
suicidal ideationSignal1288.37.0812
feeling abnormalSignal2867.16.31,494
inappropriate schedule of product administrationSignal1856.15.3783
anxietySignal2284.74.2676
tremorSignal1304.63.9368
depressionSignal1754.53.9485
dizzinessSignal3283.93.5716
somnolenceSignal1163.42.8196
insomniaSignal1132.52.1102
headache1551.51.323
fatigue1771.31.216
nausea1791.31.215
off label use1751.21.05
drug ineffective2301.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.